Autolus Therapeutics plc (F:6A3A) — Market Cap & Net Worth
Market Cap & Net Worth: Autolus Therapeutics plc (6A3A)
Autolus Therapeutics plc (F:6A3A) has a market capitalization of $348.45 Million (€298.05 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #14351 globally and #1422 in its home market, demonstrating a -9.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Autolus Therapeutics plc's stock price €1.19 by its total outstanding shares 266143286 (266.14 Million). Analyse Autolus Therapeutics plc cash conversion from operations to see how efficiently the company converts income to cash.
Autolus Therapeutics plc Market Cap History: 2018 to 2026
Autolus Therapeutics plc's market capitalization history from 2018 to 2026. Data shows change from $7.39 Billion to $370.27 Million (-30.67% CAGR).
Autolus Therapeutics plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Autolus Therapeutics plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
65.80x
Autolus Therapeutics plc's market cap is 65.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $7.39 Billion | $1.41 Million | -$44.75 Million | 5254.38x | N/A |
| 2019 | $3.61 Billion | $2.91 Million | -$123.85 Million | 1241.17x | N/A |
| 2020 | $2.18 Billion | $242.00K | -$142.09 Million | 9000.19x | N/A |
| 2021 | $1.34 Billion | $2.33 Million | -$142.10 Million | 574.22x | N/A |
| 2022 | $516.51 Million | $6.19 Million | -$148.84 Million | 83.39x | N/A |
| 2023 | $1.84 Billion | $1.70 Million | -$208.38 Million | 1081.14x | N/A |
| 2024 | $665.86 Million | $10.12 Million | -$220.66 Million | 65.80x | N/A |
Competitor Companies of 6A3A by Market Capitalization
Companies near Autolus Therapeutics plc in the global market cap rankings as of May 5, 2026.
Key companies related to Autolus Therapeutics plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Autolus Therapeutics plc Historical Marketcap From 2018 to 2026
Between 2018 and today, Autolus Therapeutics plc's market cap moved from $7.39 Billion to $ 370.27 Million, with a yearly change of -30.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €370.27 Million | -26.54% |
| 2025 | €504.06 Million | -24.30% |
| 2024 | €665.86 Million | -63.73% |
| 2023 | €1.84 Billion | +255.42% |
| 2022 | €516.51 Million | -61.40% |
| 2021 | €1.34 Billion | -38.57% |
| 2020 | €2.18 Billion | -39.66% |
| 2019 | €3.61 Billion | -51.18% |
| 2018 | €7.39 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Autolus Therapeutics plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $348.45 Million USD |
| MoneyControl | $348.45 Million USD |
| MarketWatch | $348.45 Million USD |
| marketcap.company | $348.45 Million USD |
| Reuters | $348.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; A… Read more